PPD, Inc. engages in the provision of drug development services to the biopharmaceutical industry, focuses on helping customers bring their new medicines to patients around the world. It operates through the Clinical Development Services and Laboratory Services segments. The Clinical Development Services segment focuses in early development/Phase I, patient recruitment and enrollment, investigator site management, Phase II-IV clinical trial management, medical communications and various peri- and post-approval services. The Laboratory Services segment comprises of bioanalytical, vaccine sciences, GMP, central lab and biomarker testing. The company was founded by Fred Eshelma in 1985 and is headquartered in Wilmington, NC.

WILMINGTON, N.C.--(BUSINESS WIRE)--PPD has been named “Most Innovative CRO” by North Carolina's Triangle Business Journal.

PPD Named ‘Most Innovative CRO' by Triangle Business Journal

SUZHOU, China--(BUSINESS WIRE)--PPD held a grand opening event for its new multipurpose lab in Suzhou, China, to support pharma and biotech companies managing China research studies

PPD Opens Multipurpose Clinical Research Laboratory in Suzhou, China

WILMINGTON, N.C.--(BUSINESS WIRE)--PPD has been recognized for excellence in the CRO Leadership Awards, earning praise for its clinical research capabilities and customer compatibility.

CRO Leadership Awards Recognize PPD for Excellence for 10th Consecutive Year

Weingarten Realty

NEW YORK, May 13, 2021 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq. WeissLaw LLP1500 Broadway, 16th Floor New York, NY 10036 (212) 682-3025(888) 593-4771 stockinfo@weisslawllp.com Weingarten Realty Investors (NYSE: WRI)WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Weingarten Realty Investors (NYSE: WRI) in connection with the proposed cash-and-stock acquisition of the company by Kimco Realty Corporation ("Kimco").

SHAREHOLDER ALERT: WeissLaw LLP Reminds WRI, PPD, VKIN, and GNBF Shareholders About Its Ongoing Investigations

WILMINGTON, N.C.--(BUSINESS WIRE)--PPD was named “Best Contract Research Organization” at the 14th annual Vaccine Industry Excellence Awards during the 2021 World Vaccine Congress

PPD Named “Best CRO” at Vaccine Industry Excellence Awards

PPD, Inc. (PPD) CEO David Simmons on Q1 2021 Results - Earnings Call Transcript

WILMINGTON, N.C.--(BUSINESS WIRE)--PPD is expanding its Athlone, Ireland, GMP (good manufacturing practices) laboratory

PPD to Expand GMP Lab in Ireland to Enhance Biopharmaceutical Testing Capabilities

PPD, Inc. (PPD) delivered earnings and revenue surprises of 12.90% and 6.79%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

PPD, Inc. (PPD) Q1 Earnings and Revenues Top Estimates

Shares of PPD (NASDAQ:PPD) rose in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 45.83% year over year to $0.35, which beat the estimate of $0.31.

PPD: Q1 Earnings Insights

WILMINGTON, N.C.--(BUSINESS WIRE)--PPD Reports First Quarter 2021 Results

PPD Reports First Quarter 2021 Results

WILMINGTON, N.C. & LOS ANGELES--(BUSINESS WIRE)--PPD and Science 37 Strengthen Collaboration to Advance Decentralized Clinical Trials and Accelerate Development

PPD and Science 37® Strengthen Collaboration to Advance Decentralized Clinical Trials and Accelerate Development

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of PPD, Inc. (NASDAQ: PPD) to Thermo Fisher Scientific Inc. for $47.50 per share is fair to PPD shareholders. Halper Sadeh encourages PPD shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether PPD and its board of

PPD Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of PPD, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – PPD

PPD, Inc. (PPD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

PPD, Inc. (PPD) Soars 6.5%: Is Further Upside Left in the Stock?

NEW YORK, April 15, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of PPD, Inc. ("PPD" or the "Company") (NASDAQ: PPD) in connection with the proposed acquisition of the Company by Thermo Fisher Scientific Inc. (NYSE: TMO). Under the terms of the merger agreement, PPD shareholders will receive $47.50 in cash for each share of PPD common stock that they hold.

SHAREHOLDER ALERT: WeissLaw LLP Investigates PPD, Inc.

PALO ALTO, Calif.--(BUSINESS WIRE)-- #biotech--Medable announced $78 million in new funding to fuel advances in the delivery of decentralized clinical trials and patient-centered research.

Medable Secures Another $78 Million Funding to Fuel Digital Innovation for Patient-Centered Drug Development

Thermo Fisher Scientific

Shares of PPD Inc. rallied 7.3% in premarket trading Thursday, after Thermo Fisher Scientific Inc. confirmed an agreement to buy the pharmaceutical-testing company in a cash deal valued at $17.4 billion, including $3.5 billion in debt. Thermo Fisher shares gained 3.1% ahead of the open.

Thermo Fisher to buy PPD, in a cash deal valued at $17.4 billion including debt

Thermo Fisher Scientific to Acquire PPD, Inc., a Leading Clinical Research Organization

The stock price of PPD Inc (NASDAQ: PPD) increased by 12.1%. This is why it happened.

PPD Stock: 12.1% Increase Explanation

WILMINGTON, N.C.--(BUSINESS WIRE)--PPD Announces First Quarter 2021 Earnings Conference Call

PPD Announces First Quarter 2021 Earnings Conference Call

Charles River Laboratories

Clinical trial leaders PPD and Charles River Labs test resistance and new buy points. The post Clinical Trial Leaders PPD And CRL Stock Test New Buy Points appeared first on Investor's Business Daily.

Clinical Trial Leaders PPD And CRL Stock Test New Buy Points

WILMINGTON, N.C.--(BUSINESS WIRE)--PPD and Clinical Ink have developed a systemic lupus erythematosus (SLE) assessment review process to simplify clinical trials for the chronic disease

PPD and Clinical Ink Collaborate on Innovative Process for Lupus Assessment and Near Real-Time Access to Endpoint Data

WILMINGTON, N.C.--(BUSINESS WIRE)--PPD has been recognized for industry leadership in digital and decentralized clinical trial solutions by Information Services Group (ISG)

PPD Named a Leader in Digital Clinical Trial Solutions by ISG

PPD, Inc. (PPD) CEO David Simmons on Q4 2020 Results - Earnings Call Transcript

PPD, Inc. (PPD) delivered earnings and revenue surprises of 11.43% and 6.39%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

PPD, Inc. (PPD) Tops Q4 Earnings and Revenue Estimates

Shares of PPD (NASDAQ:PPD) were flat in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 18.18% over the past year to $0.39, which beat the estimate of $0.36.

News for PPD Stock (PPD)